key: cord-1056161-mjzbubs5
authors: Kashour, Zakariya; Riaz, Muhammad; Garbati, Musa A; AlDosary, Oweida; Tlayjeh, Haytham; Gerberi, Dana; Murad, M Hassan; Sohail, M Rizwan; Kashour, Tarek; Tleyjeh, Imad M
title: Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis
date: 2020-10-08
journal: J Antimicrob Chemother
DOI: 10.1093/jac/dkaa403
sha: a13676a6dae38b974f3a380ae603049e05deac77
doc_id: 1056161
cord_uid: mjzbubs5

OBJECTIVES: Clinical studies of chloroquine (CQ) and hydroxychloroquine (HCQ) in COVID-19 disease reported conflicting results. We sought to systematically evaluate the effect of CQ and HCQ with or without azithromycin on outcomes of COVID-19 patients. METHODS: We searched multiple databases, preprints and grey literature up to 17 July 2020. We pooled only adjusted-effect estimates of mortality using a random-effect model. We summarized the effect of CQ or HCQ on viral clearance, ICU admission/mechanical ventilation and hospitalization. RESULTS: Seven randomized clinical trials (RCTs) and 14 cohort studies were included (20 979 patients). Thirteen studies (1 RCT and 12 cohort studies) with 15 938 hospitalized patients examined the effect of HCQ on short-term mortality. The pooled adjusted OR was 1.05 (95% CI 0.96–1.15, I(2) = 0%). Six cohort studies examined the effect of the HCQ+azithromycin combination with a pooled adjusted OR of 1.32 (95% CI 1.00–1.75, I(2) = 68.1%). Two cohort studies and four RCTs found no effect of HCQ on viral clearance. One small RCT demonstrated improved viral clearance with CQ and HCQ. Three cohort studies found that HCQ had no significant effect on mechanical ventilation/ICU admission. Two RCTs found no effect for HCQ on hospitalization risk in outpatients with COVID-19. CONCLUSIONS: Moderate certainty evidence suggests that HCQ, with or without azithromycin, lacks efficacy in reducing short-term mortality in patients hospitalized with COVID-19 or risk of hospitalization in outpatients with COVID-19.

The COVID-19 pandemic has claimed hundreds of thousands of human lives and caused enormous economic damage. While the race to develop an effective vaccine continues, repurposing of approved drugs remains the most logical treatment approach for SARS-CoV-2 infection and its complications.

Since the discovery of the antiviral effects of chloroquine (CQ) and hydroxychloroquine (HCQ) more than 50 years ago, interest in exploring their therapeutic potential against various viral infections has continued relentlessly. 1 CQ/HCQ have been tested against numerous viruses, such as HIV-1, SARS, MERS-CoV, influenza, dengue, Ebola, Zika, Chikungunya and other viruses. [2] [3] [4] [5] [6] [7] [8] [9] [10] V C The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Several mechanisms have been proposed for the anti-SARS-CoV-2 effects of CQ/HCQ. All of which are secondary to their ability to raise intracellular pH, which particularly affects endosome function. 11, 12 CQ/HCQ can interfere with all stages of the viral life cycle. 11 They have the potential to hinder SARS-CoV-2 binding to its cell membrane receptor, ACE2, through their interference with the glycosylation process of the ACE2 protein that results in reducing its binding affinity to SARS-CoV-2 virus. CQ/HCQ could also prevent fusion of the viral particles to the host cell membrane and prevent their cell entry. Furthermore, CQ/HCQ can also inhibit viral replication, assembly and release of viral particles from the host cells. 11 CQ/HCQ also alter endosomal antigen processing and modulate both the innate and adaptive immune responses. 11, 12 This leads to decreased production of pro-inflammatory cytokines, such as TNFa, IL-1b and IL-6. Additionally, CQ/HCQ improve endothelial function and reduce the prothrombotic state. 13 These properties could have favourable effects in patients with severe COVID-19 disease.

With the emergence of SARS-CoV-2 virus and its rapid spread across the globe, it was natural to test the antiviral effects of CQ/ HCQ against this new threatening infection. The enthusiasm for their widespread clinical use in the treatment of COVID-19 disease escalated with the early studies reporting their effective in vitro antiviral effects against SARS-CoV-2 virus. 14- 16 An early interim analysis of 100 COVID-19 patients was reported by a group from China where they found that CQ therapy was associated with less severe pneumonia, shorter disease course and faster viral clearance. 17 Another small nonrandomized study of 20 patients from France revealed reduced nasopharyngeal viral carrier state at 6 days after the initiation of treatment with HCQ and azithromycin. 18 These limited data along with the political support for CQ/HCQ use led clinicians worldwide to use them indiscriminately and to include them in their institutional protocols and guidelines for the treatment of COVID-19 disease as a monotherapy or in combination with azithromycin. This rapid adoption of CQ/HCQ was associated with an astronomical increase in CQ/HCQ prescription of approximately 2000%. 19 While numerous large randomized clinical trials (RCTs) were started in different countries worldwide, several observational studies addressing the efficacy and safety of CQ/HCQ in the treatment of COVID-19 disease got published along with preliminary results from some RCTs. These studies have different methodologies and sample sizes, and produced mixed results, ranging from reduced mortality and improved other clinical outcomes to increased mortality among COVID-19 patients.

The absence of robust clinical evidence for their efficacy, as well as the potential serious drug-induced adverse events associated with CQ/HCQ use, call for rigorously conducted systematic reviews/ meta-analyses of the available clinical data to present a clearer picture about their efficacy and provide a data-informed view regarding their utility in the treatment of COVID-19. In this study, we set out to perform a systematic review and meta-analysis of the literature regarding the efficacy of CQ or HCQ in patients with COVID-19.

We followed PRISMA ('Preferred Reporting Items for Systematic Reviews and Meta-Analyses') 20 guidelines for reporting a systematic review and meta-analysis of observational studies. We included (i) RCTs or (ii) cohort or case-control studies reporting on adjusted-effect estimates of the association between HCQ or CQ with or without azithromycin and the following endpoints: (i) short-term mortality, (ii) mechanical ventilation/ICU admission and (iii) viral clearance among hospitalized patients with COVID-19 and (iv) risk for hospitalization among outpatients with COVID-19.

The literature was searched by a medical librarian for the concepts of CQ or HCQ combined with COVID-19. The search strategies were created using a combination of keywords and standardized index terms. Searches were run up to 17 July 2020 in Ovid EBM Reviews, Ovid Embase (1974!), Ovid Medline (1946! including epub ahead of print, in-process and other nonindexed citations), Scopus (1970!) and Web of Science (1975!). Search strategies are provided in Tables S1 to S4 (available as Supplementary data at JAC Online). We also searched for unpublished manuscripts using the medRxiv services operated by Cold Spring Harbor Laboratory and Research Square preprints. In addition, we searched Google Scholar and the references of eligible studies and review articles.

Two reviewers independently identified eligible studies (Z.K. and O.A.) and four reviewers (Z.K., M.A.G., O.A. and H.T.) extracted the data into a prespecified data collection form. A senior reviewer verified all data included in the analyses (I.M.T.).

Two reviewers (Z.K. and O.A.) independently assessed risk of bias for each study using RoB 2 of the Cochrane risk-of-bias tool for randomized trials 21 and the Newcastle-Ottawa scale for cohort studies and case-control studies. 22 Reviewers judged each criterion for risk of bias and resolved any disagreements by discussion with a third senior reviewer. We assessed the certainty of evidence for each of our outcomes using the GRADE ('Grading of Recommendations Assessment, Development and Evaluations') approach. 23, 24 This method evaluates the certainty of evidence by assessing the following domains: limitations, indirectness, inconsistency, imprecision and publication bias.

We pooled studies using the DerSimonian-Laird random-effects model (and constructed corresponding forest plots). Pooled adjusted-effect estimates (ORs and HRs) were obtained by combining the estimates of log adjusted-effect estimate from each study. Endpoints that we considered a priori for the meta-analysis were: (i) short-term mortality, (ii) mechanical ventilation/ICU admission and (iii) viral clearance among hospitalized patients with COVID-19 and (iv) risk for hospitalization among outpatients with COVID-19. We evaluated heterogeneity using the I 2 statistic, which estimates the variability percentage in effect estimates that is due to heterogeneity rather than to chance-the larger the I 2 , the greater the heterogeneity. We conducted sensitivity analyses to assess the impact of (i) risk of bias in included studies and (ii) the selection of study population (general populations versus specific populations) on the overall estimate of effect. We constructed funnel plots and performed an Egger precision-weighted linear regression test as a statistical test of funnel plot asymmetry and publication bias. All analyses were conducted using Stata version 16 statistical software (StataCorp, College Station, TX, USA).

Out of 1896 papers screened for eligibility, 7 RCTs 25-31 and 14 cohort studies [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] were included ( Figure 1 ) with a total of 20 979 patients. Characteristics of included studies are described in Tables 1 and 2. Characteristics of the patients in each study can be found in Table S5 . Nineteen studies (5 RCTs and 14 cohort Systematic review studies) [25] [26] [27] [28] [29] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] with 20 263 patients reported on cases hospitalized with COVID-19. Two RCTs 30,31 studied 358 participants in the outpatient setting and one cohort study 32 included both inpatients and outpatients (57 versus 37, respectively). Most of the studies included patients presenting with varying levels of disease severity. Yu et al. 43 only studied patients with critical disease, whereas Geleris et al. 34 and Mahévas et al. 41 excluded them.

The quality of the observational studies was assessed using the Newcastle-Ottawa scale (Table S11) . With regards to patient selection, all but four studies had adequate representation of a general population with COVID-19 infection. Sánchez-Á lvarez et al. 33 and Alberici et al. 32 studied haemodialysis patients, Yu et al. 43 studied patients with severe COVID-19 infection and Kuderer et al. 36 studied patients with cancer. With regards to comparability, three studies 32,33,44 did not adequately adjust for confounders in their analyses. Given the relatively short course of disease, all studies were considered to have had a satisfactory follow-up duration. Three studies 32, 33, 43 that assessed mortality were considered at high risk of bias and a sensitivity analysis was performed by excluding these studies to assess heterogeneity. The results of the Cochrane RoB 2 assessment for RCTs can be found in Table S12 . Of the five included RCTs, three were considered high risk, [27] [28] [29] one was low risk 25 and one had no available manuscript for quality assessment. 26 Some studies were initially included in our review as eligible studies, but were later excluded for various reasons. Chen et al. 46 only reported time to clinical recovery and changes in radiological parameters and Feng et al. 47 reported disease progression in patients receiving CQ. Four studies were excluded over serious methodology concerns [48] [49] [50] [51] and one study was retracted due to concerns over the validity of the patient information. 52 GRADE was used to assess the certainty of evidence for each outcome. The findings were then summarized, along with the overall certainty of evidence (Table 3) .

Outcome data and analytical methods reported by included studies are summarized in Tables S6 to S10. , indicating no significant association between HCQ and mortality ( Figure 2 ). There was moderate heterogeneity among the included studies. In a sensitivity analysis, after excluding the three studies with high risk of bias 32,33,43 the pooled adjusted OR was 1.05 (95% CI 0.96-1.15, I 2 = 0%) ( Figure 3) . In an analysis restricted to cohort studies, the pooled adjusted OR was 0.90 (95% CI 0.73-1.09, I 2 = 57%) ( Figure S1 ). A total of six cohort studies [35] [36] [37] [38] [39] [40] with 3430 patients examined the effect of the HCQ!azithromycin combination on mortality. The pooled adjusted OR was 1.32 (95% CI 1.00-1.75, I 2 = 68.1%), with a higher odds for mortality in the combination therapy group compared with the control group (Figure 4) . Excluding the study of Kuderer et al., 36 that included only patients with cancers, eliminated this heterogeneity (adjusted OR = 1.15, 95% CI 0.99-1.34, I 2 = 0.0%).

There was no publication bias on visual inspection of funnel plots ( Figures S2 to S5) . Additionally, Egger's regression did not detect any significant publication bias (P = 0.276).

Six studies in our meta-analysis evaluated the effect of therapy on viral clearance, of which five had a high risk of bias and, thus, effect estimates were not pooled together.

Four RCTs (two with a high risk of bias, 28,29 one with a moderate risk of bias 30 and one with a low risk of bias; 25 assessed using Cochrane RoB 2) and two cohort studies 44, 45 (with a high risk of bias; assessed using the Newcastle-Ottawa scale) assessed the effect of HCQ on viral clearance. One RCT 29 demonstrated significant improvement in time to viral clearance (2.0 days; IQR 2.0-3.5), two 25 

Three cohort studies assessed the association between HCQ and the composite outcome of mechanical ventilation or ICU admission. 38, 40, 41 None of the studies found any association between HCQ and the composite outcome [1.1 (95% CI 0.476-2.5), 1.43 (95% CI 0.53-3.79) and 0.81 (95% CI 0.55-1.18), respectively].

Additionally, two cohort studies 38, 40 failed to demonstrate any significant association between HCQ!azithromycin and the composite outcome of mechanical ventilation or ICU admission 

Our systematic review and meta-analysis included 12 cohort studies and 1 RCT, which addressed the association between HCQ therapy and mortality in patients hospitalized with COVID-19 disease. Among a total of 19 573 patients, we found, with a moderate level of certainty, that HCQ monotherapy did not reduce short-term mortality among COVID-19 patients, which remained statistically non-significant even after excluding three studies at high risk of bias. These observations did not change when we included in the model only the cohort studies. Moreover, we found that the use of the combination HCQ!azithromycin was associated with a trend of increased mortality. The study by Kuderer et al. 36 analysed cancer patients and demonstrated higher mortality than other studies, creating significant heterogeneity. Excluding this study did not decrease the risk of mortality. Because of the limited number of studies and/or high risk of bias, we could not conduct a metaanalysis of other clinical outcomes, such as viral clearance, risk of ICU admission and need for mechanical ventilation. We also observed that two RCTs found no significant effect for HCQ on hospitalization risk in outpatients with mild or moderate COVID-19.

Our findings of lack of efficacy of HCQ in the inpatient and outpatient clinical setting despite its effective in vitro inhibitory actions against SARS-CoV-2 virus is consistent with previous observations with other viral illnesses. Numerous studies demonstrated significant in vitro inhibitory effects of CQ/HCQ against coronaviruses and non-coronaviruses. 11 For example, CQ at EC 50 of 8.8 ± 1.2 lM effectively inhibited SARS-CoV replication in Vero E6 cells. 3 CQ was also shown to inhibit MERS-CoV and alphacoronavirus HCoV-229E replication in vitro in a dose-dependent manner. 4 Likewise, CQ/ HCQ exhibited in vitro inhibitory effects against several other viruses, such as HIV-1, influenza, dengue, Ebola, Zika, Chikungunya and other viruses. 2,5-10 Although CQ/HCQ have shown consistent broad-spectrum in vitro antiviral effects, their in vivo and clinical antiviral effects were disappointing. For instance, CQ was ineffective in preventing or ameliorating influenza following viral challenge in mouse and ferret models 5 and did not prevent influenza infection in a randomized, double-blind placebo-controlled trial in humans. 53 CQ also resulted in worse outcomes in a guinea pig model of Ebola infection 7 and was shown to enhance Chikungunya viral infections in different animal models, including non-human primates. 54 Moreover, CQ was ineffective in improving the course of Chikungunya viral infection in humans. 54 ,55 CQ was also tested in a randomized controlled trial of 307 patients with dengue virus and failed to reduce duration of viraemia or NS1 antigenaemia. 56 In the case of HIV-1, the use of CQ/HCQ was inconclusive and hence they were not endorsed for routine use in the treatment of HIV-1 infection. 57 Possible reasons for lack of efficacy of HCQ in the treatment of COVID-19 disease

The discrepancy between the observed in vitro anti-SARS-CoV-2 effects of CQ/HCQ and the lack of efficacy in clinical studies, which mirrors previous observations with other viral infections, could be due to three main reasons.

First, most in vitro studies employ pre-treatment protocols, where cells are treated with the drugs before infecting them with the tested virus. In vitro studies that compared pre-treatment and post-infection treatment have shown that CQ/HCQ have less effective antiviral activities if added after infection. 4, 16, 58 For example, Vincent et al. 58 showed that CQ at 0.1, 1.0 and 10 lM added 20-24 h before infection with SARS-CoV decreased infectivity by 28%, 53% and 100%. However, if CQ is added 3-5 h after infecting the cells, higher concentrations of CQ of up to 50 lM were needed to decrease infectivity. 58 This may raise the possibility that chronic or prophylactic use of CQ/HCQ may reduce the risk of acquiring SARS-CoV-2 infection. However, a recent large population study of 14 250 individuals showed that chronic use of HCQ was not protective against SARS-CoV-2 infection. 59 Second, a wide range of EC 50 values were reported for CQ and HCQ and, in the case of SARS-CoV-2, the EC 50 for CQ ranges between 1.13 and 7.36 lM and between 0.72 and 17.31 lM for HCQ. 11 It is worth noting that the lowest EC 50 of 0.72 lM for HCQ reported by Yao et al. 16 in their post-infection experiments was different from the lowest EC 50 of 5.85 lM in their pre-treatment experiments. None of the other investigators reported such a low EC 50 for CQ of HCQ with SARS-CoV-2 or any other viruses. Achieving adequate blood and tissue drug concertation is essential for proper antiviral activity. In mice, a high dose of 90 mg/kg twice a day of CQ was necessary to achieve steady-state blood levels of 2.5 lg/mL. 8 High doses of CQ/HCQ in COVID-19 patients can be associated with increased adverse events, as shown in a recent RCT, where high-dose CQ was shown to be associated with significant toxicity in COVID-19 patients. 60 In addition, optimal CQ or HCQ blood levels for effective antiviral action are unclear, since the suggested levels were based on widely differing in vitro EC 50 estimates. In a study of 40 HIV-1 patients treated with HCQ 800 mg/ day for 8 weeks, the HCQ blood concentration range was 0.27-1.0 lg/mL. 61 Only those HIV-1 patients who achieved the highest HCQ blood concentrations had a favourable response to HCQ. 61 There are only two small studies that looked at the pharmacokinetics of HCQ in COVID-19 patients. 18, 62 In the first study, Gautret et al. 18 found that the mean HCQ level in 20 patients treated with HCQ 600 mg/day was 0.46 lg/mL. This blood concentration is lower than the lowest effective in vitro concentration of 0.72 lM. Perinel et al. 62 showed that only 61% of 13 patients treated with HCQ 600 mg/day achieved what they considered the minimum therapeutic concentration of 1 lg/mL with a mean time to reach this concentration of 2.7 days. Based on published data and their own, Balevic et al. 63 found that the average serum/plasma HCQ concentration was below the lowest antiviral target level for SARS-CoV-2 of 0.48 lg/mL in all studies. These studies indicate that current HCQ dosing is probably suboptimal to achieve adequate blood levels necessary for effective antiviral activity.

Third, antimalarials exhibit anti-inflammatory and immunomodulatory effects, decreasing the production of pro-inflammatory cytokines and improving endothelial function and reducing the prothrombotic state. 12, 13 These effects would be very beneficial in patients with severe COVID-19 disease; however, HCQ reduces the affinity of toll-like receptor 7 and 9 (TLR7 and TLR9) to viral RNA and also inhibits the cyclic GMP-AMP synthase pathway and hence it inhibits the type I interferon response, which is the first line of defence of the innate immune system against viral infections. 12 This effect might counteract the direct antiviral effects of HCQ and reduce its efficacy in treating COVID-19 disease.

Further research is needed to address these important issues to improve the clinical utility of CQ/HCQ for the treatment of COVID-19 disease, which should include exploring alternate administration routes like intranasal application and inhalation therapy.

Our meta-analysis not only revealed lack of efficacy of HCQ in improving the outcomes of COVID-19 patients, but also suggested possible increased risk of mortality when used in combination with azithromycin. Several studies have shown increased risk of cardiac toxicity among COVID-19 patients treated with CQ/HCQ. Our group have recently conducted a meta-analysis on CQ/HCQ-induced cardiac toxicity in COVID-19 patients, 64 which revealed increased risk of QTc prolongation and discontinuation of drug due to QT prolongation. In addition, CQ/HCQ were associated with a clinically significant risk of malignant arrhythmias and cardiac arrest. 60 It has also been a common practice to use HCQ in combination with azithromycin for COVID-19 during the current pandemic. Azithromycin has been linked to increased risk of sudden cardiac death. 65, 66 Hence, the concomitant use of CQ/HCQ and azithromycin or other QT-prolonging agents could potentially increase the risk of serious cardiac arrhythmias and death. Increased risk of 30 day cardiac death, angina and heart failure complications associated with the combination therapy of HCQ!azithromycin has also been reported in a recent preprint of a large population study of 323 122 patients. 67 Our findings are consistent with the IDSA recommendations on the use of CQ/HCQ in COVID-19 disease 68 and the recent systematic reviews. [69] [70] [71] However, our study has several advantages over the previous reviews (Table S13) . First, it is the only study that included both qualitative and quantitative analyses. Second, it has the largest number of identified studies and therefore patient population because our search is the most up to date. Third, in contrast to all previous studies, we included only studies that reported adjusted-effect estimates and therefore we avoided including studies at high risk of bias due to confounding. Fourth, we provided adequate assessment of the certainty of evidence using the GRADE classification. Finally, we offered a comprehensive discussion regarding the probable mechanisms of lack of efficacy of HCQ in COVID-19, which will inform and stimulate further research in this area.

This meta-analysis has several strengths. Firstly, published and unpublished studies were included, which reduces publication bias. We also employed rigorous methodologies, where we excluded studies that did not report adjusted ORs or HRs and those with poor methodology. We analysed and reported monotherapy and combination therapy separately. We also examined mortality and other clinical outcomes separately and performed sensitivity analyses to eliminate sources of between-study heterogeneity. However, our study has several limitations; all of our included studies except one were observational studies, which are prone to bias; including confounding by allocation, survival bias and residual confounding. Our group and others have shown that survivor bias, which occurs because patients who live longer are more likely to receive treatment than those who die early, could change associations from benefit to harm. 72, 73 Moreover, as with all observational studies, residual confounding could weaken any observed association 74 even with appropriate adjustment or propensity score matching. Nevertheless, the direction of these biases is supposed to be in favour of HCQ efficacy. In addition, our pooled estimates are consistent with the results of the interim report from the RECOVERY trial, which lends support to our findings.

This systematic review and meta-analysis indicates, with a moderate level of certainty, that HCQ monotherapy lacks efficacy in reducing short-term mortality in hospitalized patients with COVID-19 or in reducing risk of hospitalization in outpatients with COVID-19. We also found that the use of HCQ in combination with azithromycin is probably associated with increased shortterm mortality among hospitalized COVID-19 patients.

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

None to declare.

Published in the preprint server medRxiv (2020; 2020.07.12.20150110).

Tables S1 to S13 and Figures S1 to S5 are available as Supplementary data at JAC Online.

Comparison of the antiviral activity in vitro of some nonsteroidal anti-inflammatory drugs

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Screening of an FDAapproved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Chloroquine is effective against influenza A virus in vitro but not in vivo

Chloroquine interferes with dengue-2 virus replication in U937 cells

Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

an endocytosis blocking agent, inhibits Zika virus infection in different cell models

Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in Vero cells

Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review

Rethinking the role of hydroxychloroquine in the treatment of COVID-19

Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

RoB 2: a revised tool for assessing risk of bias in randomised trials

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Clinical practice guidelines: a primer on development and dissemination

Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial

Treating COVID-19 with chloroquine

Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial

Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial

A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection

Report of the COVID-19 registry of the Spanish Society of Nephrology (SEN)

Observational study of hydroxychloroquine in hospitalized patients with Covid-19

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France

Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States-realworld evidence from a federated electronic medical record network

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study

Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

The use of adjuvant therapy in preventing progression to severe pneumonia in patients with coronavirus disease 2019: a multicenter data analysis

Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study

Clinical Outcomes of Hydroxychloroquine in Hospitalized Patients With COVID-19: A Quasi-Randomized Comparative Study

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Risk factors for mortality in patients with COVID-19 in New York City

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection

On Chikungunya acute infection and chloroquine treatment

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults

The enigma of the clandestine association between chloroquine and HIV-1 infection

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1

Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients

Hydroxychloroquine in patients with rheumatic disease complicated by COVID-19: clarifying target exposures and the need for clinical trials

The cardiac toxicity of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and metaregression analysis

Azithromycin and the risk of cardiovascular death

Azithromycin causes a novel proarrhythmic syndrome

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study

Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19

Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis

Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review

Should clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19? Living practice points from the American College of Physicians (version 1)

Survival biases lead to flawed conclusions in observational treatment studies of influenza patients

Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias

The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study